April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
The Rate of Topographic Optic Disc Change is Faster in Eyes Developing POAG Than in Eyes Not Developing POAG: The Confocal Scanning Laser Ophthalmoscopy (CSLO) Ancillary Study to the Ocular Hypertension Treatment Study (OHTS)
Author Affiliations & Notes
  • L. M. Zangwill
    Ophthalmology, Univ of California-San Diego, Hamilton Glaucoma Center, La Jolla, California
  • S. Jain
    Family and Preventive Medicine, Univ of California-San Diego, La Jolla, California
  • R. N. Weinreb
    Ophthalmology, Univ of California-San Diego, Hamilton Glaucoma Center, La Jolla, California
  • G. L. Trick
    Ophthalmology, Henry Ford Health System, Detroit, Michigan
  • J. D. Brandt
    Univ of California-Davis Eye Center, Sacramento, California
  • G. A. Cioffi
    Ophthal-Discoveries in Sight, Devers Eye Institute, Portland, Oregon
  • A. L. Coleman
    Jules Stein Institute-UCLA, Los Angeles, California
  • J. Piltz-Seymour
    University of Pennsylvania Health Systems, Bristol, Pennsylvania
  • M. A. Kass
    Ophthalmology, Washington Univ Sch of Med, St Louis, Missouri
  • CSLO Ancillary Study to the OHTS Study Group
    Ophthalmology, Univ of California-San Diego, Hamilton Glaucoma Center, La Jolla, California
  • Footnotes
    Commercial Relationships  L.M. Zangwill, Heidelberg Engineering, Heidelberg Germany, F; Carl Zeiss Meditec Inc, Dublin, CA, F; S. Jain, None; R.N. Weinreb, Carl Zeiss Meditec, Inc., C; Glaxo, C; Carl Zeiss Meditec, Inc., F; Heidelberg Engineering, GmbH, F; Novartis, F; Optovue, Inc., F; Topcon Medical Systems, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Optovue, Inc., C; Pfizer, Inc., C; Topcon Medical Systems, Inc., C; G.L. Trick, Allergan, Inc., C; J.D. Brandt, Alcon Laboratories, Inc., C; Allergan, Inc., C; Pfizer, Inc., C; Alcon Laboratories, Inc., R; Allergan, Inc., R; Pfizer, Inc., R; G.A. Cioffi, Allergan, Inc., C; Pfizer Inc, C; A.L. Coleman, Alcon Laboratories, Inc., C; Allergan, Inc., C; Pfizer, Inc., C; J. Piltz-Seymour, None; M.A. Kass, Pfizer Inc, C.
  • Footnotes
    Support  NIH/NEI grants, EY11158 (RNW), (EY09341, EY09307 (MOG, MAK)), Horncrest Foundation awards, NIH Vision Core Grant P30 EY02687, Merck Research Laboratories, Pfizer Inc, White House Station, New Jersey,
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2048. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. M. Zangwill, S. Jain, R. N. Weinreb, G. L. Trick, J. D. Brandt, G. A. Cioffi, A. L. Coleman, J. Piltz-Seymour, M. A. Kass, CSLO Ancillary Study to the OHTS Study Group; The Rate of Topographic Optic Disc Change is Faster in Eyes Developing POAG Than in Eyes Not Developing POAG: The Confocal Scanning Laser Ophthalmoscopy (CSLO) Ancillary Study to the Ocular Hypertension Treatment Study (OHTS). Invest. Ophthalmol. Vis. Sci. 2010;51(13):2048.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare rates of change in topographic optic disc parameters in ocular hypertensive eyes that do/do not develop primary open angle glaucoma (POAG) and to evaluate factors that influence the rate of change.

Methods: : The rate of change of Heidelberg Retina Tomograph (HRT) optic disc parameters was measured in 439 participants (866 eyes) in the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS (median follow-up: 10 years, with 50 participants (64 eyes) developing POAG, defined by OHTS criteria by visual fields and/or stereo-photographs. Multivariable mixed effects models adjusting for baseline age, visual field PSD, stereophotograph-based horizontal cup disc ratio corneal thickness, IOP, race and disc area were used to compare slopes of topographic optic disc parameters in eyes that did/did not develop POAG.

Results: : The slope of rim area loss was significantly different from zero in eyes that did and did not develop POAG (both p<0.0001). In both univariate and multivariable analyses, the rate of rim area loss (95% CI) was significantly faster in eyes developing POAG than in eyes that did not (univariate rate: -0.014 (-0.018, -0.009) mm2/yr and -0.002 (-0.015, -0.007) mm2/yr, respectively). The rates of change of other topographic optic disc parameters including cup volume, and rim disc ratio were also significantly faster in eyes that developed POAG compared to eyes that did not. In multivariable analyses, the slope of loss was consistently greater in eyes with larger stereo-photograph based cup disc ratios at baseline.

Conclusions: : The rate of structural change is approximately 5 times faster in eyes that developed POAG compared to eyes that did not. These results suggest that measuring the rate of structural change can provide important information for the clinical management of ocular hypertensive patients.

Clinical Trial: : www.clinicaltrials.gov NCT00000125

Keywords: optic disc • clinical (human) or epidemiologic studies: systems/equipment/techniques • imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×